SBTX logo

SkinBioTherapeutics plc Stock Price

AIM:SBTX Community·UK£40.8m Market Cap
  • 0 Narratives written by author
  • 1 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

SBTX Share Price Performance

UK£0.16
-0.02 (-10.00%)
UK£0.16
-0.02 (-10.00%)
Price UK£0.16

SBTX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet and fair value.

3 Risks
2 Rewards

SkinBioTherapeutics plc Key Details

UK£4.6m

Revenue

UK£1.8m

Cost of Revenue

UK£2.9m

Gross Profit

UK£3.6m

Other Expenses

-UK£696.3k

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.0027
61.65%
-15.01%
6.4%
View Full Analysis

About SBTX

Founded
2015
Employees
41
CEO
Stuart Ashman
WebsiteView website
www.skinbiotherapeutics.com

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Recent SBTX News & Updates

Recent updates

No updates